You are here: Industry Insights > Kevzara

News List

Clinical programme to evaluate Kevzara® as COVID-19 treatment begins europeanpharmaceuticalreview
March 19, 2020
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
Sanofi and Regeneron trial Kevzara to treat severe Covid-19 pharmaceutical-technology
March 17, 2020
Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.
Sanofi and Regeneron to assess Kevzara to treat Covid-19 pharmaceutical-technology
March 12, 2020
Sanofi and Regeneron Pharmaceuticals have plans to initiate clinical trials of rheumatoid arthritis drug Kevzara for the treatment of Covid-19 symptoms.
Sanofi and Regeneron to simplify antibody partnership pharmaceutical-technology
December 12, 2019
Sanofi and Regeneron Pharmaceuticals have said the companies may transform their antibody partnership, which involves Kevzara (sarilumab) and Praluent (alirocumab) drugs ...
Sanofi, Regeneron splitting up on Praluent, Kevzara fiercepharma
December 11, 2019
After more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recently on the back of strong sales of blockbuster Dupixent.
Final NICE nod for Sanofi’s Kevzara pharmatimes
November 03, 2017
The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).
Sanofi's arthritis treatment Kevzara secures NICE recommendation pharmafile
September 26, 2017
Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its final appraisal determination on the company’s Kevzara (sarilumab)
Sanofi and Regeneron announce EC approval of Kevzara (sarilumab) expressbpd
June 28, 2017
It is used to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union
FDA approves Kevzara for the treatment of moderately to severely active RA in adults cphi-online
May 25, 2017
Kevzara is now available to US patients.
Kevzara receives first approval in Canada cphi-online
February 06, 2017
Regeneron Pharmaceuticals and Sanofi have announced that Health Canada approved Kevzara (sarilumab). Regulatory decisions for Kevzara are anticipated in the US and European Union later this year.

Previous page 1 2 Next page